{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:40:56Z","timestamp":1771515656657,"version":"3.50.1"},"reference-count":14,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1976,8]]},"abstract":"<jats:p content-type=\"fine-print\">\u2713 Forty-one consecutive patients with supratentorial primary brain tumors (38 Grade III and IV astrocytomas, one giant-cell astrocytoma, and two cases with insufficient tissue for diagnosis) were randomly allocated within 2 weeks of surgery to one of three therapeutic groups. Group 1 (15 patients) received radiation therapy totaling 4000 to 4500 rads in 4 to 5 weeks. Group 2 (13 patients) received 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) 130 mg\/sq m orally every 6 weeks. Group 3 (13 patients) received radiation therapy plus CCNU as for Groups 1 and 2. When the disease progressed, patients in Groups 1 and 2 were crossed over to receive CCNU and irradiation respectively. The median survival time in these groups was 188, 259, and 252 days, and the mean survival 263, 262, and 329 days. The median time from diagnosis to crossover (Groups 1 and 2) or to progression (Group 3) was 163, 99, and 220 days, and the mean time was 172, 108, and 231 days. There was no statistically significant difference between the means or medians in any of these situations.<\/jats:p>","DOI":"10.3171\/jns.1976.45.2.0129","type":"journal-article","created":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T15:11:03Z","timestamp":1241709063000},"page":"129-134","source":"Crossref","is-referenced-by-count":43,"title":["Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas"],"prefix":"10.3171","volume":"45","author":[{"given":"Bryce","family":"Weir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Band","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Urtasun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Blain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Grace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"key":"b1","series-title":"Cancer Chemother Rep (Part 3)","first-page":"115","article-title":"Nitrosoureas: 1, 3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962; BCNU) and 1-(2-chloroethyl)3-cyclohexyl-1-nitrosourea (NSC-79037; CCNU) \u2014 clinical brochure.","volume":"1","author":"Carter","year":"1968"},{"key":"b2","series-title":"Clin Pharmacol Ther","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/cpt196784566","article-title":"The physiological disposition of the carcinostatic 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) in man and animals.","volume":"8","author":"DeVita","year":"1967"},{"key":"b3","series-title":"Cancer Chemother Rep","first-page":"421","article-title":"Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.","volume":"56","author":"Fewer","year":"1972"},{"key":"b4","series-title":"Cancer Chemother Rep","first-page":"99","article-title":"Treatment of malignant brain tumors with nitrosoureas.","volume":"55","author":"Hansen","year":"1971"},{"key":"b5","series-title":"Cancer Chemother Rep (Part 3)","first-page":"13","article-title":"Toxicology and pharmacology of the nitrosoureas.","volume":"4","author":"Oliviero","year":"1973"},{"key":"b6","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3171\/jns.1973.39.3.0306","article-title":"Chloroethyl-cyclohexyl-nitrosourea (CCNU) in the treatment of malignant brain tumors.","volume":"39","author":"Rosenblum","year":"1973"},{"key":"b7","series-title":"Clin Bull","first-page":"90","article-title":"Malignant brain tumor chemotherapy: Part II. Clinical studies.","volume":"3","author":"Shapiro","year":"1973"},{"key":"b8","series-title":"J Natl Cancer Inst","first-page":"359","article-title":"Studies on the chemotherapy of experimental brain tumors: evaluation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vin-cristine, and 5-fluorouracil.","volume":"46","author":"Shapiro","year":"1971"},{"key":"b9","series-title":"Cancer Res","first-page":"2401","article-title":"Studies on the chemotherapy of experimental brain tumors: evaluation of 1, 3-bis (2-chloroethyl)-1-nitrosourea, cyclophosphamide, mithramycin and methotrexate.","volume":"30","author":"Shapiro","year":"1970"},{"key":"b10","series-title":"Cancer Chemother Rep (Part 3)","first-page":"21","article-title":"Nitrosoureas in central nervous system tumors.","volume":"4","author":"Walker","year":"1973"},{"key":"b11","series-title":"Pro Am Assoc Cancer Res","first-page":"67","article-title":"An evaluation of 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and irradiation alone and in combination for the treatment of malignant glioma.","volume":"13","author":"Walker","year":"1972"},{"key":"b12","series-title":"Cancer Chemother Rep","first-page":"263","article-title":"BCNU (1, 3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor \u2014 a preliminary report.","volume":"54","author":"Walker","year":"1970"},{"key":"b13","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3171\/jns.1973.38.4.0448","article-title":"The relative significance of factors affecting postoperative survival in astrocytomas, grades 3 and 4.","volume":"38","author":"Weir","year":"1973"},{"key":"b14","series-title":"Cancer Chemother Rep","first-page":"273","article-title":"1, 3-bis(2-chloroethyl)-1-nitrosourea (NSC 409962) in the treatment of brain tumors.","volume":"54","author":"Wilson","year":"1970"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/45\/2\/article-p129.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/45\/2\/article-p129.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/45\/2\/article-p129.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T05:24:20Z","timestamp":1658726660000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/45\/2\/article-p129.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1976,8]]},"references-count":14,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/jns.1976.45.2.0129","relation":{},"ISSN":["0022-3085"],"issn-type":[{"value":"0022-3085","type":"print"}],"subject":[],"published":{"date-parts":[[1976,8]]}}}